Digital Reproductive Health Leader YunCheng Secures Tens of Millions in Series A Funding Amid Market Headwinds

VCBeat has learned that YunCheng, a digital reproductive health brand, recently announced the completion of its tens-of-millions-yuan Series A financing round. Investors in this round include Shenzhen Jiuchuan and the Anji Liangshan Mass Entrepreneurship and Innovation Fund, with existing shareholder TusStar continuing to participate. The funds raised will be primarily used to accelerate product development and clinical trials, attract top talent, strengthen organizational infrastructure, and expand marketing and promotional efforts.

Yuncheng focuses on digital diagnostic platforms and the industrialization of smart IoT in the field of at-home self-testing. The COVID-19 pandemic has significantly accelerated consumer demand for rapid at-home testing and access to professional medical services. Yuncheng currently enters the market by focusing on women’s reproductive health, particularly among individuals facing infertility and those seeking optimal pregnancy outcomes, thereby supporting the effective implementation of China’s new fertility policies.

The most effective and immediate lever for realizing the impact of new fertility policies is the population experiencing infertility. This group exhibits the strongest desire and most urgent need for childbearing. In China, one in seven couples faces difficulties conceiving, amounting to over 50 million couples—a substantial market. Currently, the market focuses on assisted reproductive technologies (ART) while overlooking digital therapeutics for reproductive health. The latter serves as a beneficial complement to ART, and together they can significantly improve pregnancy rates among individuals struggling with infertility.

Yuncheng’s digital therapeutics (diagnostic) technology for assisted reproduction integrates medical science with digital innovation, centering on a mobile app and intelligent in vitro diagnostics to deliver personalized interventions for individuals experiencing infertility. By leveraging artificial intelligence and novel home-based testing technologies, it precisely monitors key indicators such as physiological signs and hormone levels, offering users subscription-based services that include ovulation tracking, timed intercourse guidance, lifestyle interventions, and professional educational content.

With the rising awareness of gender equality and the growing purchasing power of women, the female health technology (hereinafter referred to as “Femtech”) market is flourishing. Femtech refers to software, diagnostic technologies, related products, and services specifically focused on women’s health.

In 2021, there were 35 financing events related to women’s digital health globally, with the total funding amount exceeding $1 billion for the first time. The global women’s digital health industry is projected to reach a valuation of $4.7 billion by 2027, with more companies and Femtech startups offering telemedicine solutions.

Currently, among the four female digital health companies that have successfully completed initial public offerings (IPOs) globally, two are directly engaged in fertility and fertility management. Industry leaders such as Flo and Modern Fertility have also secured hundreds of millions of dollars in financing in recent years.

According to a recent report by Femtech Analytics, pregnancy and care, reproductive health, and contraception account for approximately 37% of the global Femtech market. Digital reproductive health is a crucial component of Femtech, providing significant support for female fertility.

Digital reproductive health is grounded in the core medical principle of the Fertility Awareness Method (FAM). It primarily leverages digital monitoring and big data analytics of multiple fertility indicators—such as basal body temperature, sexual hormone test strips, and cervical mucus—to deliver personalized, precision services and provide visualized data management, empowering consumers to take control of their fertility.

Currently, many domestic apps remain at the level of menstrual period tracking tools. They lack professional tools and content related to fertility awareness-based methods, as well as specialized medical-grade algorithms and user data derived from real-world studies. This often results in inaccurate data analysis, making it difficult to gain recognition from both healthcare professionals and users.

Pregnancy Orange specializes in the Fertility Awareness Method (FAM) medical technology and an intelligent IoT platform. It possesses a physiological cycle database with over one billion annotated female records. Leveraging the research prowess of its core team, composed of master’s and doctoral graduates from Tsinghua University and Peking University, the company has integrated the German-originated FAM with real-world data from female users both domestically and internationally. This effort led to the development of the iFAM algorithm, which is currently used by over 6 million users worldwide. The algorithm has also received professional endorsement from dozens of industry stakeholders, including Beijing Obstetrics and Gynecology Hospital, Aviation General Hospital, Jinxin Fertility, Merck China, Wondfo, and Mama.cn. As regulatory policies for digital therapeutics become more refined, algorithmic accuracy and medical certification capabilities are emerging as core competitive barriers.

Yuncheng boasts a professionally complementary core team composed of elite talent from Tsinghua University and Peking University, overseas returnees, and key executives from publicly listed companies. The founder, Dr. Wang Yin, is a distinguished alumnus of Tsinghua University, having completed his bachelor’s, master’s, doctoral, and postdoctoral studies there. He brings nearly two decades of experience in the industry-academia-research integration of intelligent IoT and digital health. In collaboration with leading domestic and international experts in gynecological endocrinology, he co-developed the underlying core technology of the “Yuncheng Conception Awareness Method.” Partners Zhiwei Zuo, Junzhou Li, and Xiuying Tan are responsible for product development, marketing, and financing/investment, respectively, each possessing over twenty years of industry experience. The founding team hails from renowned enterprises such as Pfizer, SAP, Cisco, JD.com, and Chunyu Doctors. Yuncheng is repositioning itself as a brand provider of products and services in digital reproductive health and plans to enter the broader market for digital at-home self-testing through a multi-brand strategy in the future.

Yu Yongping, Secretary-General of the Life Sciences and Medical Health Committee of the Tsinghua Alumni Association, and Investor at YunChengIt stated that home self-testing represents a new blue-ocean market worth hundreds of billions of yuan. The current in vitro diagnostics (IVD) industry is facing a structural opportunity to shift from business-to-business (2B) to business-to-consumer (2C) models, with the greatest value of digital diagnostics lying in its ability to deliver results that are immediately recognized by physicians. Starting from the high-demand preconception segment of the digital reproductive health market, YunCheng has developed core capabilities to create integrated hardware-software home self-testing products for consumers. In the future, it can expand into the hundred-billion-yuan female reproductive endocrine market, covering stages such as adolescence, contraception, post-pregnancy, postpartum, and menopause, as well as into home healthcare sectors including respiratory care, infectious diseases, and chronic disease management. The digital diagnostics platform it has built for home self-testing holds substantial value.

Yang Le, Fund Manager at Shenzhen JiuchuanIt was stated that the number of newborns in China approached 10 million in 2021, marking a new low compared to the previous sixty years. Following the introduction of the “universal three-child policy” in May 2021, enabling individuals who desire children but face difficulties conceiving to achieve pregnancy sooner has become key to addressing the continued decline in newborn numbers. YunCheng has long focused on the field of digital reproductive health for women, serving populations seeking optimal conception, those with difficulty conceiving, and those experiencing infertility. By empowering female reproductive health through artificial intelligence and the Internet of Things, and by establishing competitive barriers via core algorithms and medical device licenses, Jiuchuan remains firmly optimistic about YunCheng’s leading position and moat in the field of female reproductive health.

Zou Jin, Chairman of Anji Two Mountains State-owned Holdings GroupIt was mentioned that Liangshan has consistently focused on and supported forward-looking and innovative technology companies. YunCheng leverages Internet of Things (IoT), big data, and artificial intelligence technologies to develop medical-grade digital therapeutics for female reproductive health, while also expanding into a broader home-based self-testing digital diagnostics platform. This approach brings greater efficiency and more consistent quality to the traditional healthcare industry, enhancing user experience while reducing medical costs and improving the accessibility of healthcare services, promising a bright future ahead.